PNPLA3 and metabolic dysfunction-associated steatohepatitis: Based on such promising outcomes, an ASO compound, namely ION839, is registered for phase 1 clinical trials in obese NASH subjects homozygous for the PNPLA3 risk variant (NCT04142424, NCT04483947).